BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16791271)

  • 1. Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
    Moon HW; Shin S; Kim HY; Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Chun H; Kim HC; Park CJ; Min YH; Lee DS
    Leukemia; 2006 Aug; 20(8):1408-13. PubMed ID: 16791271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia.
    Yoo SJ; Chi HS; Jang S; Seo EJ; Seo JJ; Lee JH; Park HS; Park CJ
    Haematologica; 2005 Nov; 90(11):1493-501. PubMed ID: 16266896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.
    Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G
    Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
    Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
    Ehlers S; Herbst C; Zimmermann M; Scharn N; Germeshausen M; von Neuhoff N; Zwaan CM; Reinhardt K; Hollink IH; Klusmann JH; Lehrnbecher T; Roettgers S; Stary J; Dworzak M; Welte K; Creutzig U; Reinhardt D
    J Clin Oncol; 2010 May; 28(15):2591-7. PubMed ID: 20406937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
    Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.
    Cho EK; Bang SM; Ahn JY; Yoo SM; Park PW; Seo YH; Shin DB; Lee JH
    Korean J Intern Med; 2003 Mar; 18(1):13-20. PubMed ID: 12760263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon.
    Shimizu K; Kitabayashi I; Kamada N; Abe T; Maseki N; Suzukawa K; Ohki M
    Blood; 2000 Jul; 96(1):288-96. PubMed ID: 10891464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions.
    Gamerdinger U; Teigler-Schlegel A; Pils S; Bruch J; Viehmann S; Keller M; Jauch A; Harbott J
    Genes Chromosomes Cancer; 2003 Mar; 36(3):261-72. PubMed ID: 12557226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
    Rhoades KL; Hetherington CJ; Rowley JD; Hiebert SW; Nucifora G; Tenen DG; Zhang DE
    Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11895-900. PubMed ID: 8876234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1-ETO positive AML: first report from India.
    Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
    Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose dependent long-term in vivo remission of AML1/ETO positive acute myeloid leukemia with G-CSF.
    Zomas A; Stefanoudaki-Sofianatou K; Fisfis M; Anagnostopoulos NI
    Hematology; 2004 Apr; 9(2):107-11. PubMed ID: 15203865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF and GM-CSF concentrations and receptor expression in peripheral blood leukemic cells from patients with chronic myelogenous leukemia.
    Lee J; Kim Y; Lim J; Kim M; Han K
    Ann Clin Lab Sci; 2008; 38(4):331-7. PubMed ID: 18988925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
    Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
    Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of acute myelogenous leukemia with the same AML1/ETO breakpoint as at diagnosis after complete remission lasting 15 years: analysis of stored bone marrow smears.
    Tsukamoto N; Karasawa M; Tanaka Y; Yokohama A; Uchiumi H; Matsushima T; Murakami H; Nojima Y
    Int J Hematol; 2003 Nov; 78(4):362-9. PubMed ID: 14686496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease].
    Qin YZ; Li JL; Zhu HH; Li LD; Chang Y; Hao L; Wang YZ; Jiang B; Lu XJ; Liu YR; Huang XJ; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):441-5. PubMed ID: 19035174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetic findings in a three-way novel variant of t(1;8;21)(p35;q22;q22): a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2.
    Ahmad F; Kokate P; Chheda P; Dalvi R; Das BR; Mandava S
    Cancer Genet Cytogenet; 2008 Jan; 180(2):153-7. PubMed ID: 18206543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
    Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
    Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of aml-1/eto fusion gene in patients with acute myeloid leukemia by real-time quantitative RT-PCR].
    Jiang YM; Yuan H; Liu XY; Wang B; Li SJ; Wang N
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):17-22. PubMed ID: 19236739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.